Navigation Links
Japan Pharma Review: Outlook to 2017

NEW YORK, Sept. 20, 2012 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Japan Pharma Review: Outlook to 2017

Japan's pharmaceutical industry is in the midst of a defining period. The sector has evolved dramatically over the past decade, as companies attempt to gain ground on their Western peers in meeting the demands of global healthcare markets.Analysis of Japan Pharma's domestic and international competitive environmentAssess Japan Pharma's strategy for driving growth and extending its global reachWhile the top 10 companies in Japan Pharma are dominant within their domestic market, generating more than half of overall prescription pharma revenues in Japan, a range of factors have provided the impetus for companies to expand their global footprint.Evaluate the drivers and resistors of sales growth for the Japan Pharma peer set, both in its domestic market and overseasAssess Japan Pharma's strategic opportunities to bolster its performance


SCOPE OF ANALYSIS•PharmaVitae Explorer database



•Japan Pharma's expanding global footprint - Closing the gap on Big Pharma

- Japan still a stronghold for domestic players

- US revenues set for 25% decline; focus shifting towards areas of unmet need

- Takeda – leading the trend in globalization

- External strategies employed to reinforce long-term growth



HISTORICAL EVOLUTION OF JAPAN PHARMA•Introduction - Corporate evolution of Japan Pharma


JAPAN PHARMA DOMESTIC MARKET ANALYSIS: FOCUS ON JAPAN•Key domestic growth drivers - Aging Japanese population

- Japan Pharma focus shifting towards chronic disease areas


•Key domestic growth resistors - Domestic outlook is positive overall despite downward pressures


JAPAN PHARMA INTERNATIONAL MARKET ANALYSIS: FOCUS ON GLOBALIZATION•International drivers and resistors - Japan Pharma geographical positioning

- Overseas products offer greater likelihood of reaching blockbuster revenues

- Upsurge in overseas acquisitions by Japan Pharma


•Financial catalysts of Japan Pharma's international position - Strong balance sheet provides springboard for M&A

- Currency fluctuations have greatly enhanced the overseas purchasing power of Japan Pharma


•Product portfolio dynamics - Positive impact of externally sourced products on sales performance

- Pipelines are increasingly focused on international development

- Shift towards oncology drug development

- Expiry impact – generic erosion in the US is trigger for M&A

- Shift away from the blockbuster model



•Exchange rates



•Table: Datamonitor's established pharmaceutical company coverage, 2012

•Table: Top 10 companies in Japan Pharma, sales ($m), 2005–17

•Table: Exchange rates, 2012



•Figure: The PharmaVitae Explorer

•Figure: Evolution of Japan Pharma's corporate strategy

•Figure: Top 10 prescription pharmaceutical companies in Japan in 2011 (Japan FY2012)

•Figure: Global prescription pharmaceutical sales, split by region (% of total sales)

•Figure: Summary of drivers and resistors in the domestic Japanese market

•Figure: Leading pharmaceutical companies' prescription pharmaceutical sales in Japan, 2011

•Figure: Japanese population distributed by age (millions of people)

•Figure: Japan Pharma domestic growth forecast by therapy area

•Figure: Generic usage by volume in major markets

•Figure: Japan Pharma domestic sales by age of drug (in years)

•Figure: Japan Pharma combined sales forecast in domestic market

•Figure: Summary of drivers and resistors impacting Japan Pharma globalization strategy

•Figure: Global pharmaceutical sales by company, 2011

•Figure: Geographical focus of Japan Pharma vs Global Pharma, 2011

•Figure: Overseas sales of Japan Pharma, 2005–11

•Figure: Japan Pharma overseas market focus, 2011

•Figure: Japan Pharma's top 20 products by sales, 2011

•Figure: Japan Pharma's cash vs debt, 2006–11

•Figure: Historical exchange rate of yen vs US dollar, euro, and pound, January 2007 to January 2012

•Figure: Overseas sales of Japan Pharma by product source, 2005–17

•Figure: Japan Pharma global clinical development pipeline, Phase I to registration

•Figure: Japan Pharma global clinical development pipeline by therapy area

•Figure: Japan Pharma expiry sales forecast, 2011–17

•Figure: Overseas sales of top 10 Japan Pharma companies by drug value


Companies Mentioned

Abbott Laboratories, Actelion Ltd, Allergan, Inc., Amgen, Inc., Astellas Pharma Inc., Baxter International Inc., Bayer AG, Biogen Idec, Inc., Bristol-Myers Squibb Company, Celgene Corporation, CSL Limited, F. Hoffmann-La Roche Ltd, Forest Laboratories, Inc., Gilead Sciences, Inc., GlaxoSmithKline Plc, H. Lundbeck A/S, Hutchison 3G UK Limited, Janssen Pharmaceuticals, Inc., Les Laboratoires Servier, Merck KGaA, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Shire plc


To order this report:

Pharmaceutical Industry: Japan Pharma Review: Outlook to 2017

Nicolas Bombourg
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CMC Biologics Establishes Commercial Presence in Japan through Strategic Agreement with Innomedica
2. Pfizer and Mylan Team Up to Establish Exclusive Long-Term Strategic Collaboration to Drive Sustained Growth of Generics Business in Japan
3. Pharmaceutical Supply Chain in Japan - Periodic Drug Price Revisions by National Health Insurance Increase Competition and Squeeze Profit Margins
4. Japanese Market for Orthopedic Soft Tissue Repair & Sports Medicine
5. CPhI Japan Triumphs in the Prestigious AEO Excellence Awards
6. Accuray Rolls Out Comprehensive Customer Service Program in Japan
7. Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
8. Empire Genomics Chooses Funakoshi as Japan Distributor
9. United Therapeutics Announces Collaboration With Ascendis Pharma To Develop Self-Injectable Treprostinil For Pulmonary Arterial Hypertension
10. FDAnews announces Third Annual Pharmaceutical Labeling Summit
11. JHP Pharmaceuticals to Produce Lyophilized Biologic for International Late-Phase Clinical Trials
Post Your Comments:
(Date:11/25/2015)...  Linden Care, LLC, a retail specialty pharmacy focused ... suffering from chronic pain, said today that it is ... (TRO) enjoining Express Scripts from unilaterally terminating the Pharmacy ... --> --> The company said that ... --> --> In ...
(Date:11/25/2015)... USA , Inc., a leader in ... accuracy of its blood glucose meter systems. Last week ... Cardiovascular Disease in Los Angeles , ... 01 meter and the Assure ® Prism multi-user ... measure glucose levels in blood is essential for people ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan plc (NYSE: ... agreement with the New York State ... of the Sherman Act, and other statutes with the Attorney ... February 2014, to cease marketing and selling the now generic ... settlement, Allergan admits no liability, has released its counterclaims against ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... 26, 2015 , ... PRMA Plastic Surgery is updating their record books yet ... 6,000th free flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, ... lives and it’s an honor to have served all of these women.” , PRMA ...
(Date:11/26/2015)... Viejo, CA (PRWEB) , ... November 26, 2015 ... ... users a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This ... style options. These classically-influenced trailer titles work with any font, giving users limitless ...
(Date:11/26/2015)... ... ... Inc., developer and distributor of the world-class Asterisk based contact center software Q-Suite, announces ... new Q-Suite 6 platform is based on the latest Java Enterprise standards. By conforming ... of software for many key components of the suite. Much of the suite runs ...
(Date:11/25/2015)... ... November 25, 2015 , ... As part of a ... ™ attracts volunteers together who want to combine talents and resources to help ... in the process. The non-profit launched its first major fundraiser on November 6, ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the traditional and far-infrared ... traditional and far-infrared saunas. , For traditional saunas, Finnleo is offering ... sauna wood, and Finnleo uses only European Grade A Nordic White Spruce from sustainably ...
Breaking Medicine News(10 mins):